LURASIDONE DEMONSTRATED EFFICACY IN TREATING PATIENTS WITH SCHIZOPHRENIA IN PIVOTAL PHASE 3 STUDY
Published at: www.pipelinereview.com
-
State Medicaid Cuts May Limit Market for New Antipsychotic Lurasidone
August 30, 2009
Lurasidone is an atypical antipsychotic owned by Dainippon Sumitomo Pharma. Phase 3 PEARL 1 Study: 6-week, multi-site, double-blind placebo-controlled trial in 500 pts with DSM4 schizophrenia with PANSS score greater than 80. RESULTS: 80mg dose was superior to placebo; 40mg & 120mg was not. MAIN side effects: akathisia, somnolence, Parkinsonism, weight gain. Similar to Abilify market (AstraZeneca). Economic factors which reduce the potential market are discussed.
-
Lurasidone will be an important new option for the treatment of Schizophrenia
August 29, 2009
After much disappointment over the current Atypical Antipsychotics , Lurasidone shows great promise for treatment refractory Schizophrenics.
- Subscribe to Updates
-
Work for one of the world's leading organizations? Get started now.
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 9 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Gerson Lehrman Group, Inc. connects communities with knowledge through two distinct, yet complementary offerings: GLG Research and G+.